Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Most patients with newly diagnosed multiple myeloma (MM) are aged> 65 years with 30%
aged> 75 years. Many elderly patients are also vulnerable because of comorbidities that …

Background Lenalidomide has tumoricidal and immunomodulatory activity against multiple
myeloma. This double-blind, multicenter, randomized study compared melphalan …

The treatment of multiple myeloma has changed dramatically in the past decade. The
increase in the number of active agents has generated numerous possible drug …

Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma
(MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal …

Maintaining results of successful induction therapy is an important goal in multiple myeloma.
Here, members of the International Myeloma Working Group review the relevant data …

Using population-based data from Sweden, we identified all multiple myeloma (MM) patients
(n= 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) …

Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant
in elderly patients because the major benefit results from the initial therapy. We report the …

In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for
relapsed/refractory multiple myeloma (MM; N= 3846), the overall incidence rate (IR, events …

In this Perspective, we summarize some of the most contentious issues surrounding
diagnosis and treatment of myeloma. We outline how a fundamental clash of philosophies …